nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabrafenib—SIK1—Circadian rythm related genes—TNFRSF11A—Paget's disease of bone	0.00738	0.118	CbGpPWpGaD
Dabrafenib—Back pain—Tiludronate—Paget's disease of bone	0.00703	0.0075	CcSEcCtD
Dabrafenib—Tubulointerstitial nephritis—Pamidronate—Paget's disease of bone	0.00675	0.0072	CcSEcCtD
Dabrafenib—Influenza like illness—Alendronate—Paget's disease of bone	0.00658	0.00702	CcSEcCtD
Dabrafenib—Rigors—Pamidronate—Paget's disease of bone	0.00633	0.00676	CcSEcCtD
Dabrafenib—Arthralgia—Tiludronate—Paget's disease of bone	0.00618	0.0066	CcSEcCtD
Dabrafenib—Myalgia—Tiludronate—Paget's disease of bone	0.00618	0.0066	CcSEcCtD
Dabrafenib—Neoplasm malignant—Pamidronate—Paget's disease of bone	0.00606	0.00646	CcSEcCtD
Dabrafenib—Bone disorder—Risedronate—Paget's disease of bone	0.00602	0.00643	CcSEcCtD
Dabrafenib—Hypocalcaemia—Risedronate—Paget's disease of bone	0.00594	0.00634	CcSEcCtD
Dabrafenib—Rigors—Zoledronate—Paget's disease of bone	0.00579	0.00617	CcSEcCtD
Dabrafenib—Hypocalcaemia—Pamidronate—Paget's disease of bone	0.00565	0.00603	CcSEcCtD
Dabrafenib—Neoplasm malignant—Zoledronate—Paget's disease of bone	0.00553	0.0059	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Tiludronate—Paget's disease of bone	0.0054	0.00576	CcSEcCtD
Dabrafenib—Influenza like illness—Risedronate—Paget's disease of bone	0.00528	0.00564	CcSEcCtD
Dabrafenib—Bone disorder—Zoledronate—Paget's disease of bone	0.00523	0.00558	CcSEcCtD
Dabrafenib—Oropharyngeal pain—Zoledronate—Paget's disease of bone	0.00519	0.00554	CcSEcCtD
Dabrafenib—Hypocalcaemia—Zoledronate—Paget's disease of bone	0.00516	0.00551	CcSEcCtD
Dabrafenib—Hyperkalaemia—Pamidronate—Paget's disease of bone	0.00508	0.00542	CcSEcCtD
Dabrafenib—Influenza like illness—Pamidronate—Paget's disease of bone	0.00502	0.00536	CcSEcCtD
Dabrafenib—Neoplasm—Risedronate—Paget's disease of bone	0.00492	0.00525	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Tiludronate—Paget's disease of bone	0.00485	0.00517	CcSEcCtD
Dabrafenib—Abdominal pain—Tiludronate—Paget's disease of bone	0.00469	0.005	CcSEcCtD
Dabrafenib—Hyperkalaemia—Zoledronate—Paget's disease of bone	0.00464	0.00495	CcSEcCtD
Dabrafenib—Influenza like illness—Zoledronate—Paget's disease of bone	0.00459	0.00489	CcSEcCtD
Dabrafenib—Dry skin—Alendronate—Paget's disease of bone	0.00451	0.00481	CcSEcCtD
Dabrafenib—Neoplasm—Zoledronate—Paget's disease of bone	0.00427	0.00456	CcSEcCtD
Dabrafenib—Asthenia—Tiludronate—Paget's disease of bone	0.00425	0.00454	CcSEcCtD
Dabrafenib—Cardiac failure congestive—Pamidronate—Paget's disease of bone	0.00414	0.00442	CcSEcCtD
Dabrafenib—Abdominal discomfort—Alendronate—Paget's disease of bone	0.00408	0.00435	CcSEcCtD
Dabrafenib—Renal failure acute—Pamidronate—Paget's disease of bone	0.00407	0.00434	CcSEcCtD
Dabrafenib—Diarrhoea—Tiludronate—Paget's disease of bone	0.00406	0.00433	CcSEcCtD
Dabrafenib—SIK1—TGF-beta Signaling Pathway—PML—Paget's disease of bone	0.00401	0.0639	CbGpPWpGaD
Dabrafenib—Pain in extremity—Risedronate—Paget's disease of bone	0.00395	0.00421	CcSEcCtD
Dabrafenib—Dizziness—Tiludronate—Paget's disease of bone	0.00392	0.00418	CcSEcCtD
Dabrafenib—Renal failure acute—Zoledronate—Paget's disease of bone	0.00371	0.00396	CcSEcCtD
Dabrafenib—Headache—Tiludronate—Paget's disease of bone	0.00371	0.00396	CcSEcCtD
Dabrafenib—Stomatitis—Alendronate—Paget's disease of bone	0.0037	0.00394	CcSEcCtD
Dabrafenib—Abdominal pain upper—Risedronate—Paget's disease of bone	0.00361	0.00385	CcSEcCtD
Dabrafenib—Nasopharyngitis—Risedronate—Paget's disease of bone	0.00353	0.00377	CcSEcCtD
Dabrafenib—Alopecia—Etidronic acid—Paget's disease of bone	0.00353	0.00377	CcSEcCtD
Dabrafenib—Nausea—Tiludronate—Paget's disease of bone	0.00352	0.00376	CcSEcCtD
Dabrafenib—Blood creatinine increased—Pamidronate—Paget's disease of bone	0.00352	0.00375	CcSEcCtD
Dabrafenib—Erythema—Etidronic acid—Paget's disease of bone	0.00348	0.00371	CcSEcCtD
Dabrafenib—Pain in extremity—Zoledronate—Paget's disease of bone	0.00343	0.00366	CcSEcCtD
Dabrafenib—Haemoglobin—Alendronate—Paget's disease of bone	0.00342	0.00365	CcSEcCtD
Dabrafenib—Hypokalaemia—Pamidronate—Paget's disease of bone	0.00342	0.00364	CcSEcCtD
Dabrafenib—Haemorrhage—Alendronate—Paget's disease of bone	0.0034	0.00363	CcSEcCtD
Dabrafenib—Nasopharyngitis—Pamidronate—Paget's disease of bone	0.00336	0.00358	CcSEcCtD
Dabrafenib—Oedema peripheral—Alendronate—Paget's disease of bone	0.00335	0.00358	CcSEcCtD
Dabrafenib—Muscle spasms—Etidronic acid—Paget's disease of bone	0.00334	0.00357	CcSEcCtD
Dabrafenib—Abdominal discomfort—Risedronate—Paget's disease of bone	0.00327	0.00349	CcSEcCtD
Dabrafenib—Anaemia—Etidronic acid—Paget's disease of bone	0.00321	0.00343	CcSEcCtD
Dabrafenib—Blood creatinine increased—Zoledronate—Paget's disease of bone	0.00321	0.00343	CcSEcCtD
Dabrafenib—Dehydration—Zoledronate—Paget's disease of bone	0.00319	0.0034	CcSEcCtD
Dabrafenib—Abdominal pain upper—Zoledronate—Paget's disease of bone	0.00313	0.00334	CcSEcCtD
Dabrafenib—Hypokalaemia—Zoledronate—Paget's disease of bone	0.00312	0.00333	CcSEcCtD
Dabrafenib—LIMK1—CXCR4-mediated signaling events—INPP5D—Paget's disease of bone	0.00312	0.0497	CbGpPWpGaD
Dabrafenib—Leukopenia—Etidronic acid—Paget's disease of bone	0.00311	0.00332	CcSEcCtD
Dabrafenib—Nasopharyngitis—Zoledronate—Paget's disease of bone	0.00307	0.00327	CcSEcCtD
Dabrafenib—Infestation NOS—Risedronate—Paget's disease of bone	0.00304	0.00325	CcSEcCtD
Dabrafenib—Infestation—Risedronate—Paget's disease of bone	0.00304	0.00325	CcSEcCtD
Dabrafenib—Neutropenia—Pamidronate—Paget's disease of bone	0.00303	0.00324	CcSEcCtD
Dabrafenib—Alopecia—Alendronate—Paget's disease of bone	0.00301	0.00321	CcSEcCtD
Dabrafenib—Erythema—Alendronate—Paget's disease of bone	0.00296	0.00316	CcSEcCtD
Dabrafenib—Arthralgia—Etidronic acid—Paget's disease of bone	0.00296	0.00316	CcSEcCtD
Dabrafenib—Urinary tract infection—Risedronate—Paget's disease of bone	0.00296	0.00316	CcSEcCtD
Dabrafenib—Infestation NOS—Pamidronate—Paget's disease of bone	0.00289	0.00309	CcSEcCtD
Dabrafenib—Infestation—Pamidronate—Paget's disease of bone	0.00289	0.00309	CcSEcCtD
Dabrafenib—SIK1—Circadian rythm related genes—PML—Paget's disease of bone	0.00286	0.0456	CbGpPWpGaD
Dabrafenib—Muscle spasms—Alendronate—Paget's disease of bone	0.00285	0.00304	CcSEcCtD
Dabrafenib—Renal failure—Pamidronate—Paget's disease of bone	0.00284	0.00303	CcSEcCtD
Dabrafenib—Abdominal discomfort—Zoledronate—Paget's disease of bone	0.00284	0.00303	CcSEcCtD
Dabrafenib—Infection—Etidronic acid—Paget's disease of bone	0.00282	0.00301	CcSEcCtD
Dabrafenib—Stomatitis—Pamidronate—Paget's disease of bone	0.00282	0.00301	CcSEcCtD
Dabrafenib—Urinary tract infection—Pamidronate—Paget's disease of bone	0.00281	0.003	CcSEcCtD
Dabrafenib—Neutropenia—Zoledronate—Paget's disease of bone	0.00277	0.00296	CcSEcCtD
Dabrafenib—Haematuria—Pamidronate—Paget's disease of bone	0.00276	0.00294	CcSEcCtD
Dabrafenib—Haemoglobin—Risedronate—Paget's disease of bone	0.00275	0.00293	CcSEcCtD
Dabrafenib—Anaemia—Alendronate—Paget's disease of bone	0.00274	0.00292	CcSEcCtD
Dabrafenib—Haemorrhage—Risedronate—Paget's disease of bone	0.00273	0.00291	CcSEcCtD
Dabrafenib—Urinary tract disorder—Risedronate—Paget's disease of bone	0.0027	0.00288	CcSEcCtD
Dabrafenib—Oedema peripheral—Risedronate—Paget's disease of bone	0.00269	0.00287	CcSEcCtD
Dabrafenib—Connective tissue disorder—Risedronate—Paget's disease of bone	0.00268	0.00286	CcSEcCtD
Dabrafenib—Urethral disorder—Risedronate—Paget's disease of bone	0.00268	0.00286	CcSEcCtD
Dabrafenib—Infestation NOS—Zoledronate—Paget's disease of bone	0.00264	0.00282	CcSEcCtD
Dabrafenib—Infestation—Zoledronate—Paget's disease of bone	0.00264	0.00282	CcSEcCtD
Dabrafenib—Haemoglobin—Pamidronate—Paget's disease of bone	0.00261	0.00278	CcSEcCtD
Dabrafenib—Renal failure—Zoledronate—Paget's disease of bone	0.0026	0.00277	CcSEcCtD
Dabrafenib—Haemorrhage—Pamidronate—Paget's disease of bone	0.0026	0.00277	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Etidronic acid—Paget's disease of bone	0.00259	0.00276	CcSEcCtD
Dabrafenib—Stomatitis—Zoledronate—Paget's disease of bone	0.00258	0.00275	CcSEcCtD
Dabrafenib—Urinary tract infection—Zoledronate—Paget's disease of bone	0.00257	0.00274	CcSEcCtD
Dabrafenib—Urinary tract disorder—Pamidronate—Paget's disease of bone	0.00256	0.00274	CcSEcCtD
Dabrafenib—Eye disorder—Risedronate—Paget's disease of bone	0.00255	0.00272	CcSEcCtD
Dabrafenib—Connective tissue disorder—Pamidronate—Paget's disease of bone	0.00255	0.00272	CcSEcCtD
Dabrafenib—Urethral disorder—Pamidronate—Paget's disease of bone	0.00255	0.00272	CcSEcCtD
Dabrafenib—Myalgia—Alendronate—Paget's disease of bone	0.00252	0.00269	CcSEcCtD
Dabrafenib—Haematuria—Zoledronate—Paget's disease of bone	0.00252	0.00269	CcSEcCtD
Dabrafenib—Angiopathy—Risedronate—Paget's disease of bone	0.00248	0.00264	CcSEcCtD
Dabrafenib—Immune system disorder—Risedronate—Paget's disease of bone	0.00247	0.00263	CcSEcCtD
Dabrafenib—Mediastinal disorder—Risedronate—Paget's disease of bone	0.00246	0.00263	CcSEcCtD
Dabrafenib—Arrhythmia—Risedronate—Paget's disease of bone	0.00244	0.0026	CcSEcCtD
Dabrafenib—Constipation—Etidronic acid—Paget's disease of bone	0.00243	0.00259	CcSEcCtD
Dabrafenib—Eye disorder—Pamidronate—Paget's disease of bone	0.00243	0.00259	CcSEcCtD
Dabrafenib—Infection—Alendronate—Paget's disease of bone	0.0024	0.00256	CcSEcCtD
Dabrafenib—Mental disorder—Risedronate—Paget's disease of bone	0.00239	0.00255	CcSEcCtD
Dabrafenib—Malnutrition—Risedronate—Paget's disease of bone	0.00238	0.00254	CcSEcCtD
Dabrafenib—Angiopathy—Pamidronate—Paget's disease of bone	0.00236	0.00251	CcSEcCtD
Dabrafenib—Immune system disorder—Pamidronate—Paget's disease of bone	0.00235	0.0025	CcSEcCtD
Dabrafenib—Urinary tract disorder—Zoledronate—Paget's disease of bone	0.00234	0.0025	CcSEcCtD
Dabrafenib—Mediastinal disorder—Pamidronate—Paget's disease of bone	0.00234	0.0025	CcSEcCtD
Dabrafenib—Oedema peripheral—Zoledronate—Paget's disease of bone	0.00234	0.00249	CcSEcCtD
Dabrafenib—Connective tissue disorder—Zoledronate—Paget's disease of bone	0.00233	0.00249	CcSEcCtD
Dabrafenib—Chills—Pamidronate—Paget's disease of bone	0.00233	0.00249	CcSEcCtD
Dabrafenib—Urethral disorder—Zoledronate—Paget's disease of bone	0.00233	0.00248	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Etidronic acid—Paget's disease of bone	0.00232	0.00248	CcSEcCtD
Dabrafenib—Back pain—Risedronate—Paget's disease of bone	0.0023	0.00245	CcSEcCtD
Dabrafenib—Alopecia—Pamidronate—Paget's disease of bone	0.00229	0.00245	CcSEcCtD
Dabrafenib—Muscle spasms—Risedronate—Paget's disease of bone	0.00229	0.00244	CcSEcCtD
Dabrafenib—Erythema—Pamidronate—Paget's disease of bone	0.00226	0.00241	CcSEcCtD
Dabrafenib—Malnutrition—Pamidronate—Paget's disease of bone	0.00226	0.00241	CcSEcCtD
Dabrafenib—Abdominal pain—Etidronic acid—Paget's disease of bone	0.00224	0.00239	CcSEcCtD
Dabrafenib—Eye disorder—Zoledronate—Paget's disease of bone	0.00222	0.00237	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Alendronate—Paget's disease of bone	0.0022	0.00235	CcSEcCtD
Dabrafenib—Anaemia—Risedronate—Paget's disease of bone	0.0022	0.00235	CcSEcCtD
Dabrafenib—Back pain—Pamidronate—Paget's disease of bone	0.00219	0.00233	CcSEcCtD
Dabrafenib—Muscle spasms—Pamidronate—Paget's disease of bone	0.00217	0.00232	CcSEcCtD
Dabrafenib—Angiopathy—Zoledronate—Paget's disease of bone	0.00215	0.0023	CcSEcCtD
Dabrafenib—Immune system disorder—Zoledronate—Paget's disease of bone	0.00214	0.00229	CcSEcCtD
Dabrafenib—Mediastinal disorder—Zoledronate—Paget's disease of bone	0.00214	0.00228	CcSEcCtD
Dabrafenib—Chills—Zoledronate—Paget's disease of bone	0.00213	0.00227	CcSEcCtD
Dabrafenib—Arrhythmia—Zoledronate—Paget's disease of bone	0.00212	0.00226	CcSEcCtD
Dabrafenib—Alopecia—Zoledronate—Paget's disease of bone	0.0021	0.00224	CcSEcCtD
Dabrafenib—Hypersensitivity—Etidronic acid—Paget's disease of bone	0.00209	0.00223	CcSEcCtD
Dabrafenib—Anaemia—Pamidronate—Paget's disease of bone	0.00209	0.00223	CcSEcCtD
Dabrafenib—RAF1—GMCSF-mediated signaling events—INPP5D—Paget's disease of bone	0.00208	0.0332	CbGpPWpGaD
Dabrafenib—Mental disorder—Zoledronate—Paget's disease of bone	0.00208	0.00222	CcSEcCtD
Dabrafenib—Cough—Risedronate—Paget's disease of bone	0.00208	0.00221	CcSEcCtD
Dabrafenib—Constipation—Alendronate—Paget's disease of bone	0.00207	0.00221	CcSEcCtD
Dabrafenib—Malnutrition—Zoledronate—Paget's disease of bone	0.00206	0.0022	CcSEcCtD
Dabrafenib—Erythema—Zoledronate—Paget's disease of bone	0.00206	0.0022	CcSEcCtD
Dabrafenib—Hypertension—Risedronate—Paget's disease of bone	0.00205	0.00219	CcSEcCtD
Dabrafenib—Myalgia—Risedronate—Paget's disease of bone	0.00202	0.00216	CcSEcCtD
Dabrafenib—Arthralgia—Risedronate—Paget's disease of bone	0.00202	0.00216	CcSEcCtD
Dabrafenib—Leukopenia—Pamidronate—Paget's disease of bone	0.00202	0.00216	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Risedronate—Paget's disease of bone	0.00201	0.00215	CcSEcCtD
Dabrafenib—Pruritus—Etidronic acid—Paget's disease of bone	0.00201	0.00214	CcSEcCtD
Dabrafenib—Back pain—Zoledronate—Paget's disease of bone	0.002	0.00213	CcSEcCtD
Dabrafenib—Muscle spasms—Zoledronate—Paget's disease of bone	0.00199	0.00212	CcSEcCtD
Dabrafenib—RAF1—Endothelin Pathways—CALCA—Paget's disease of bone	0.00198	0.0316	CbGpPWpGaD
Dabrafenib—Dry mouth—Risedronate—Paget's disease of bone	0.00198	0.00211	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Alendronate—Paget's disease of bone	0.00198	0.00211	CcSEcCtD
Dabrafenib—Cough—Pamidronate—Paget's disease of bone	0.00197	0.0021	CcSEcCtD
Dabrafenib—BRAF—mTOR signaling pathway—PML—Paget's disease of bone	0.00196	0.0313	CbGpPWpGaD
Dabrafenib—Hypertension—Pamidronate—Paget's disease of bone	0.00195	0.00208	CcSEcCtD
Dabrafenib—Vision blurred—Zoledronate—Paget's disease of bone	0.00195	0.00208	CcSEcCtD
Dabrafenib—Diarrhoea—Etidronic acid—Paget's disease of bone	0.00194	0.00207	CcSEcCtD
Dabrafenib—Infection—Risedronate—Paget's disease of bone	0.00193	0.00206	CcSEcCtD
Dabrafenib—Myalgia—Pamidronate—Paget's disease of bone	0.00192	0.00205	CcSEcCtD
Dabrafenib—Arthralgia—Pamidronate—Paget's disease of bone	0.00192	0.00205	CcSEcCtD
Dabrafenib—Abdominal pain—Alendronate—Paget's disease of bone	0.00191	0.00204	CcSEcCtD
Dabrafenib—Body temperature increased—Alendronate—Paget's disease of bone	0.00191	0.00204	CcSEcCtD
Dabrafenib—Anaemia—Zoledronate—Paget's disease of bone	0.00191	0.00204	CcSEcCtD
Dabrafenib—Nervous system disorder—Risedronate—Paget's disease of bone	0.0019	0.00203	CcSEcCtD
Dabrafenib—RAF1—Interleukin-11 Signaling Pathway—BGLAP—Paget's disease of bone	0.00189	0.0301	CbGpPWpGaD
Dabrafenib—Skin disorder—Risedronate—Paget's disease of bone	0.00189	0.00201	CcSEcCtD
Dabrafenib—Leukopenia—Zoledronate—Paget's disease of bone	0.00185	0.00197	CcSEcCtD
Dabrafenib—Oedema—Pamidronate—Paget's disease of bone	0.00185	0.00197	CcSEcCtD
Dabrafenib—Infection—Pamidronate—Paget's disease of bone	0.00183	0.00196	CcSEcCtD
Dabrafenib—Nervous system disorder—Pamidronate—Paget's disease of bone	0.00181	0.00193	CcSEcCtD
Dabrafenib—Thrombocytopenia—Pamidronate—Paget's disease of bone	0.00181	0.00193	CcSEcCtD
Dabrafenib—Vomiting—Etidronic acid—Paget's disease of bone	0.0018	0.00193	CcSEcCtD
Dabrafenib—Cough—Zoledronate—Paget's disease of bone	0.0018	0.00192	CcSEcCtD
Dabrafenib—Rash—Etidronic acid—Paget's disease of bone	0.00179	0.00191	CcSEcCtD
Dabrafenib—Dermatitis—Etidronic acid—Paget's disease of bone	0.00179	0.00191	CcSEcCtD
Dabrafenib—Hyperhidrosis—Pamidronate—Paget's disease of bone	0.00178	0.0019	CcSEcCtD
Dabrafenib—Hypertension—Zoledronate—Paget's disease of bone	0.00178	0.0019	CcSEcCtD
Dabrafenib—Hypersensitivity—Alendronate—Paget's disease of bone	0.00178	0.0019	CcSEcCtD
Dabrafenib—Headache—Etidronic acid—Paget's disease of bone	0.00178	0.0019	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Risedronate—Paget's disease of bone	0.00177	0.00189	CcSEcCtD
Dabrafenib—Arthralgia—Zoledronate—Paget's disease of bone	0.00176	0.00188	CcSEcCtD
Dabrafenib—Myalgia—Zoledronate—Paget's disease of bone	0.00176	0.00188	CcSEcCtD
Dabrafenib—Insomnia—Risedronate—Paget's disease of bone	0.00176	0.00187	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—Paget's disease of bone	0.00175	0.00186	CcSEcCtD
Dabrafenib—Asthenia—Alendronate—Paget's disease of bone	0.00174	0.00185	CcSEcCtD
Dabrafenib—Hypotension—Pamidronate—Paget's disease of bone	0.00172	0.00184	CcSEcCtD
Dabrafenib—Dry mouth—Zoledronate—Paget's disease of bone	0.00172	0.00183	CcSEcCtD
Dabrafenib—RAF1—Interleukin-2 signaling—INPP5D—Paget's disease of bone	0.00172	0.0274	CbGpPWpGaD
Dabrafenib—Pruritus—Alendronate—Paget's disease of bone	0.00171	0.00183	CcSEcCtD
Dabrafenib—Nausea—Etidronic acid—Paget's disease of bone	0.00169	0.0018	CcSEcCtD
Dabrafenib—Oedema—Zoledronate—Paget's disease of bone	0.00169	0.0018	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Pamidronate—Paget's disease of bone	0.00168	0.00179	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Risedronate—Paget's disease of bone	0.00168	0.00179	CcSEcCtD
Dabrafenib—Infection—Zoledronate—Paget's disease of bone	0.00167	0.00179	CcSEcCtD
Dabrafenib—Fatigue—Risedronate—Paget's disease of bone	0.00167	0.00179	CcSEcCtD
Dabrafenib—Insomnia—Pamidronate—Paget's disease of bone	0.00167	0.00178	CcSEcCtD
Dabrafenib—RAF1—IL-3 Signaling Pathway—INPP5D—Paget's disease of bone	0.00166	0.0265	CbGpPWpGaD
Dabrafenib—Constipation—Risedronate—Paget's disease of bone	0.00166	0.00177	CcSEcCtD
Dabrafenib—Diarrhoea—Alendronate—Paget's disease of bone	0.00166	0.00177	CcSEcCtD
Dabrafenib—Nervous system disorder—Zoledronate—Paget's disease of bone	0.00165	0.00176	CcSEcCtD
Dabrafenib—Thrombocytopenia—Zoledronate—Paget's disease of bone	0.00165	0.00176	CcSEcCtD
Dabrafenib—Skin disorder—Zoledronate—Paget's disease of bone	0.00164	0.00175	CcSEcCtD
Dabrafenib—Hyperhidrosis—Zoledronate—Paget's disease of bone	0.00163	0.00174	CcSEcCtD
Dabrafenib—Decreased appetite—Pamidronate—Paget's disease of bone	0.0016	0.00171	CcSEcCtD
Dabrafenib—Dizziness—Alendronate—Paget's disease of bone	0.0016	0.00171	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Pamidronate—Paget's disease of bone	0.00159	0.0017	CcSEcCtD
Dabrafenib—Fatigue—Pamidronate—Paget's disease of bone	0.00159	0.0017	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Risedronate—Paget's disease of bone	0.00159	0.00169	CcSEcCtD
Dabrafenib—Constipation—Pamidronate—Paget's disease of bone	0.00158	0.00168	CcSEcCtD
Dabrafenib—Hypotension—Zoledronate—Paget's disease of bone	0.00157	0.00168	CcSEcCtD
Dabrafenib—Vomiting—Alendronate—Paget's disease of bone	0.00154	0.00164	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Zoledronate—Paget's disease of bone	0.00154	0.00164	CcSEcCtD
Dabrafenib—Abdominal pain—Risedronate—Paget's disease of bone	0.00153	0.00164	CcSEcCtD
Dabrafenib—Body temperature increased—Risedronate—Paget's disease of bone	0.00153	0.00164	CcSEcCtD
Dabrafenib—Rash—Alendronate—Paget's disease of bone	0.00153	0.00163	CcSEcCtD
Dabrafenib—Insomnia—Zoledronate—Paget's disease of bone	0.00152	0.00163	CcSEcCtD
Dabrafenib—Dermatitis—Alendronate—Paget's disease of bone	0.00152	0.00163	CcSEcCtD
Dabrafenib—Headache—Alendronate—Paget's disease of bone	0.00152	0.00162	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Pamidronate—Paget's disease of bone	0.00151	0.00161	CcSEcCtD
Dabrafenib—RAF1—AGE/RAGE pathway—ALPL—Paget's disease of bone	0.00147	0.0235	CbGpPWpGaD
Dabrafenib—Decreased appetite—Zoledronate—Paget's disease of bone	0.00147	0.00156	CcSEcCtD
Dabrafenib—Body temperature increased—Pamidronate—Paget's disease of bone	0.00146	0.00156	CcSEcCtD
Dabrafenib—Abdominal pain—Pamidronate—Paget's disease of bone	0.00146	0.00156	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Zoledronate—Paget's disease of bone	0.00145	0.00155	CcSEcCtD
Dabrafenib—Fatigue—Zoledronate—Paget's disease of bone	0.00145	0.00155	CcSEcCtD
Dabrafenib—Constipation—Zoledronate—Paget's disease of bone	0.00144	0.00154	CcSEcCtD
Dabrafenib—Nausea—Alendronate—Paget's disease of bone	0.00144	0.00153	CcSEcCtD
Dabrafenib—RAF1—Kit receptor signaling pathway—INPP5D—Paget's disease of bone	0.00143	0.0228	CbGpPWpGaD
Dabrafenib—Hypersensitivity—Risedronate—Paget's disease of bone	0.00143	0.00153	CcSEcCtD
Dabrafenib—RAF1—Fc-epsilon receptor I signaling in mast cells—INPP5D—Paget's disease of bone	0.00139	0.0222	CbGpPWpGaD
Dabrafenib—Asthenia—Risedronate—Paget's disease of bone	0.00139	0.00149	CcSEcCtD
Dabrafenib—BRAF—B Cell Receptor Signaling Pathway—INPP5D—Paget's disease of bone	0.00139	0.0222	CbGpPWpGaD
Dabrafenib—Gastrointestinal pain—Zoledronate—Paget's disease of bone	0.00138	0.00147	CcSEcCtD
Dabrafenib—Pruritus—Risedronate—Paget's disease of bone	0.00137	0.00147	CcSEcCtD
Dabrafenib—RAF1—Regulation of retinoblastoma protein—BGLAP—Paget's disease of bone	0.00136	0.0218	CbGpPWpGaD
Dabrafenib—Hypersensitivity—Pamidronate—Paget's disease of bone	0.00136	0.00145	CcSEcCtD
Dabrafenib—RAF1—mTOR signaling pathway—PML—Paget's disease of bone	0.00136	0.0216	CbGpPWpGaD
Dabrafenib—Abdominal pain—Zoledronate—Paget's disease of bone	0.00133	0.00142	CcSEcCtD
Dabrafenib—Body temperature increased—Zoledronate—Paget's disease of bone	0.00133	0.00142	CcSEcCtD
Dabrafenib—Diarrhoea—Risedronate—Paget's disease of bone	0.00133	0.00142	CcSEcCtD
Dabrafenib—Asthenia—Pamidronate—Paget's disease of bone	0.00132	0.00141	CcSEcCtD
Dabrafenib—Pruritus—Pamidronate—Paget's disease of bone	0.00131	0.00139	CcSEcCtD
Dabrafenib—RAF1—BCR signaling pathway—INPP5D—Paget's disease of bone	0.00129	0.0206	CbGpPWpGaD
Dabrafenib—Dizziness—Risedronate—Paget's disease of bone	0.00128	0.00137	CcSEcCtD
Dabrafenib—Diarrhoea—Pamidronate—Paget's disease of bone	0.00126	0.00135	CcSEcCtD
Dabrafenib—Hypersensitivity—Zoledronate—Paget's disease of bone	0.00124	0.00132	CcSEcCtD
Dabrafenib—Vomiting—Risedronate—Paget's disease of bone	0.00123	0.00132	CcSEcCtD
Dabrafenib—Rash—Risedronate—Paget's disease of bone	0.00122	0.00131	CcSEcCtD
Dabrafenib—Dermatitis—Risedronate—Paget's disease of bone	0.00122	0.0013	CcSEcCtD
Dabrafenib—Dizziness—Pamidronate—Paget's disease of bone	0.00122	0.0013	CcSEcCtD
Dabrafenib—Headache—Risedronate—Paget's disease of bone	0.00122	0.0013	CcSEcCtD
Dabrafenib—Asthenia—Zoledronate—Paget's disease of bone	0.00121	0.00129	CcSEcCtD
Dabrafenib—Pruritus—Zoledronate—Paget's disease of bone	0.00119	0.00127	CcSEcCtD
Dabrafenib—Vomiting—Pamidronate—Paget's disease of bone	0.00117	0.00125	CcSEcCtD
Dabrafenib—BRAF—Senescence and Autophagy in Cancer—SQSTM1—Paget's disease of bone	0.00117	0.0187	CbGpPWpGaD
Dabrafenib—Rash—Pamidronate—Paget's disease of bone	0.00116	0.00124	CcSEcCtD
Dabrafenib—Dermatitis—Pamidronate—Paget's disease of bone	0.00116	0.00124	CcSEcCtD
Dabrafenib—Headache—Pamidronate—Paget's disease of bone	0.00116	0.00123	CcSEcCtD
Dabrafenib—Diarrhoea—Zoledronate—Paget's disease of bone	0.00115	0.00123	CcSEcCtD
Dabrafenib—Nausea—Risedronate—Paget's disease of bone	0.00115	0.00123	CcSEcCtD
Dabrafenib—RAF1—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—INPP5D—Paget's disease of bone	0.00112	0.0179	CbGpPWpGaD
Dabrafenib—Dizziness—Zoledronate—Paget's disease of bone	0.00111	0.00119	CcSEcCtD
Dabrafenib—Nausea—Pamidronate—Paget's disease of bone	0.0011	0.00117	CcSEcCtD
Dabrafenib—Vomiting—Zoledronate—Paget's disease of bone	0.00107	0.00114	CcSEcCtD
Dabrafenib—Rash—Zoledronate—Paget's disease of bone	0.00106	0.00113	CcSEcCtD
Dabrafenib—Dermatitis—Zoledronate—Paget's disease of bone	0.00106	0.00113	CcSEcCtD
Dabrafenib—Headache—Zoledronate—Paget's disease of bone	0.00106	0.00113	CcSEcCtD
Dabrafenib—BRAF—Integrated Breast Cancer Pathway—PML—Paget's disease of bone	0.00101	0.0161	CbGpPWpGaD
Dabrafenib—Nausea—Zoledronate—Paget's disease of bone	0.001	0.00107	CcSEcCtD
Dabrafenib—RAF1—B Cell Receptor Signaling Pathway—INPP5D—Paget's disease of bone	0.000962	0.0153	CbGpPWpGaD
Dabrafenib—BRAF—EGF/EGFR Signaling Pathway—INPP5D—Paget's disease of bone	0.000922	0.0147	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by Interleukins—INPP5D—Paget's disease of bone	0.000882	0.0141	CbGpPWpGaD
Dabrafenib—RAF1—Senescence and Autophagy in Cancer—SQSTM1—Paget's disease of bone	0.000809	0.0129	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by Interleukins—SQSTM1—Paget's disease of bone	0.000791	0.0126	CbGpPWpGaD
Dabrafenib—RAF1—BDNF signaling pathway—ALPL—Paget's disease of bone	0.00079	0.0126	CbGpPWpGaD
Dabrafenib—RAF1—TGF-beta Signaling Pathway—PML—Paget's disease of bone	0.000779	0.0124	CbGpPWpGaD
Dabrafenib—SLCO1B3—SLC-mediated transmembrane transport—NUP205—Paget's disease of bone	0.000718	0.0115	CbGpPWpGaD
Dabrafenib—RAF1—EGF/EGFR Signaling Pathway—INPP5D—Paget's disease of bone	0.000638	0.0102	CbGpPWpGaD
Dabrafenib—SLC22A8—SLC-mediated transmembrane transport—NUP205—Paget's disease of bone	0.000636	0.0101	CbGpPWpGaD
Dabrafenib—RAF1—BDNF signaling pathway—SQSTM1—Paget's disease of bone	0.000628	0.01	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—PML—Paget's disease of bone	0.00058	0.00924	CbGpPWpGaD
Dabrafenib—SLC22A6—SLC-mediated transmembrane transport—NUP205—Paget's disease of bone	0.000531	0.00846	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by NGF—SQSTM1—Paget's disease of bone	0.000525	0.00837	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—NUP205—Paget's disease of bone	0.000483	0.0077	CbGpPWpGaD
Dabrafenib—SLCO1B1—SLC-mediated transmembrane transport—NUP205—Paget's disease of bone	0.000483	0.0077	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—NUP205—Paget's disease of bone	0.000456	0.00727	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—PML—Paget's disease of bone	0.000427	0.00681	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—INPP5D—Paget's disease of bone	0.000412	0.00657	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—PML—Paget's disease of bone	0.000403	0.00643	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—INPP5D—Paget's disease of bone	0.000389	0.0062	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—SQSTM1—Paget's disease of bone	0.000369	0.00589	CbGpPWpGaD
Dabrafenib—SLCO1B3—Transmembrane transport of small molecules—NUP205—Paget's disease of bone	0.000365	0.00582	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—SQSTM1—Paget's disease of bone	0.000363	0.00579	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—SQSTM1—Paget's disease of bone	0.000349	0.00556	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism of lipids and lipoproteins—INPP5D—Paget's disease of bone	0.000327	0.00522	CbGpPWpGaD
Dabrafenib—SLC22A8—Transmembrane transport of small molecules—NUP205—Paget's disease of bone	0.000323	0.00515	CbGpPWpGaD
Dabrafenib—BRAF—Disease—VCP—Paget's disease of bone	0.000275	0.00439	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—PML—Paget's disease of bone	0.000273	0.00436	CbGpPWpGaD
Dabrafenib—SLC22A6—Transmembrane transport of small molecules—NUP205—Paget's disease of bone	0.00027	0.0043	CbGpPWpGaD
Dabrafenib—RAF1—Transmembrane transport of small molecules—NUP205—Paget's disease of bone	0.00026	0.00415	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—INPP5D—Paget's disease of bone	0.000257	0.00409	CbGpPWpGaD
Dabrafenib—SLCO1B1—Transmembrane transport of small molecules—NUP205—Paget's disease of bone	0.000245	0.00391	CbGpPWpGaD
Dabrafenib—ABCG2—Transmembrane transport of small molecules—NUP205—Paget's disease of bone	0.000227	0.00362	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—INPP5D—Paget's disease of bone	0.000222	0.00354	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—INPP5D—Paget's disease of bone	0.00022	0.00351	CbGpPWpGaD
Dabrafenib—BRAF—Disease—NUP205—Paget's disease of bone	0.00021	0.00336	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—VCP—Paget's disease of bone	0.000193	0.00308	CbGpPWpGaD
Dabrafenib—RAF1—Disease—VCP—Paget's disease of bone	0.000191	0.00304	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—NUP205—Paget's disease of bone	0.000171	0.00273	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—NUP205—Paget's disease of bone	0.000158	0.00252	CbGpPWpGaD
Dabrafenib—BRAF—Disease—CALCA—Paget's disease of bone	0.000156	0.00249	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—INPP5D—Paget's disease of bone	0.000146	0.00233	CbGpPWpGaD
Dabrafenib—RAF1—Disease—NUP205—Paget's disease of bone	0.000146	0.00232	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—PML—Paget's disease of bone	0.000139	0.00222	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—INPP5D—Paget's disease of bone	0.000135	0.00215	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—VCP—Paget's disease of bone	0.000133	0.00213	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—CALCA—Paget's disease of bone	0.000128	0.00204	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—INPP5D—Paget's disease of bone	0.000126	0.00202	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—NUP205—Paget's disease of bone	0.000123	0.00196	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—SQSTM1—Paget's disease of bone	0.000121	0.00192	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—NUP205—Paget's disease of bone	0.000115	0.00183	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—SQSTM1—Paget's disease of bone	0.000113	0.0018	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CALCA—Paget's disease of bone	0.000109	0.00175	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CALCA—Paget's disease of bone	0.000108	0.00172	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—NUP205—Paget's disease of bone	0.000106	0.0017	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—INPP5D—Paget's disease of bone	9.8e-05	0.00156	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—INPP5D—Paget's disease of bone	9.07e-05	0.00145	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—SQSTM1—Paget's disease of bone	7.8e-05	0.00124	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CALCA—Paget's disease of bone	7.57e-05	0.00121	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—NUP205—Paget's disease of bone	6.6e-05	0.00105	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—NUP205—Paget's disease of bone	5.75e-05	0.000917	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—INPP5D—Paget's disease of bone	5.63e-05	0.000898	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—INPP5D—Paget's disease of bone	4.9e-05	0.000782	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—NUP205—Paget's disease of bone	3.54e-05	0.000565	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—INPP5D—Paget's disease of bone	3.02e-05	0.000482	CbGpPWpGaD
